Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + gemcitabine/cisplatin versus gemcitabine/cisplatin for first-line advanced or metastatic bladder cancer
NL-OMON39526Phase 2Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in bladder cancer and transitional cell carcinoma (TCC) comparing Eribulin + gemcitabine + cisplatin with Gemcitabine + cisplatin (2 arms). Primary endpoints: Maximum tolerated dose of eribulin in combination with gemcitabine and cisplatin, Safety and tolerability and 1 more. Started Aug 2010; status: active, not recruiting.
02
Drugs
eribulingemcitabinecisplatin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON39526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39526.